This article is in the news archive.
Cambridge Neuroscientists part of IMPRiND consortium
Blocking aggregate propagation in neurodegenerative diseases IMPRiND – Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases – is an international consortium that aims to map and target critical steps in the propagation of misfolded tau and α-synuclein, considered the main culprits of neurodegeneration in Alzheimer's and Parkinson's disease respectively.Their plans are built upon:
The IMPRiND consortium will construct this entire pipeline to examine the propagation of α-synuclein and tau and test their tractability against disease progression. IMPRIND started in March 2017 and will run until February 2021. IMPRiND has a total budget of 11.4 million Euros. It is supported by the IMI with 4.7 million Euros, by industrial partners with 6.4 million Euros and 0.3 million Euros from the Swiss Federation. It comprises 18 partners in 7 European countries, including 6 universities, 5 research centres, 6 pharmaceutical companies and 1 SME specialised in scientific project management.
Cambridge Neuroscientists Maria Grazia Spillantini and Michel Goedert are members of the consortium. For more information, please see the website.
Posted on 19/10/2017
Go to the news index page.